In a report released today, Louise Chen from Scotiabank maintained a Buy rating on Dyne Therapeutics (DYN – Research Report), with a price target of $50.00. The company’s shares closed last ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...